BRPI0409761A - complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo - Google Patents

complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo

Info

Publication number
BRPI0409761A
BRPI0409761A BRPI0409761-0A BRPI0409761A BRPI0409761A BR PI0409761 A BRPI0409761 A BR PI0409761A BR PI0409761 A BRPI0409761 A BR PI0409761A BR PI0409761 A BRPI0409761 A BR PI0409761A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compound
derivative
complex
phosphate
phosphate derivative
Prior art date
Application number
BRPI0409761-0A
Other languages
English (en)
Inventor
Simon Michael West
David Kannar
Original Assignee
Vital Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd
Publication of BRPI0409761A publication Critical patent/BRPI0409761A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPLEXO DE UM COMPOSTO FARMACêUTICO, FORMULAçãO ORAL, DERIVADO DE FOSFATIDILA DE UM COMPOSTO FARMACêUTICO, MéTODO PARA PREPARAçãO DE UM DERIVADO DE FOSFATO DE UM COMPOSTO FARMACêUTICO, DERIVADO DE FOSFATO DE UM COMPOSTO FARMACêUTICO E USO DO MESMO". De acordo com a invenção, é apresentado um complexo de um composto farmacêutico selecionado do grupo que consiste em opióides, hormónios, anestésicos e agentes quimioterapêuticos, o qual compreende o produto da reação (a) de um ou mais derivados de fosfato de um ou mais opióides, hormónios esteroidais, hormónios da tiróide, anestésicos ou agentes quimioterapêuticos que têm um álcool primário, álcool secundário ou um grupo hidroxila terciária fenólico; e (b) um agente formador de complexo selecionado do - grupo que compreende tensoativos anfotéricos, tensoativos catiónicos, aminoácidos que têm grupos com funcionalidade nitrogênio e proteínas ricas nestes aminoácidos.
BRPI0409761-0A 2003-04-15 2004-04-14 complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo BRPI0409761A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901813A AU2003901813A0 (en) 2003-04-15 2003-04-15 Pharmaceutical derivatives
PCT/AU2004/000492 WO2004091636A1 (en) 2003-04-15 2004-04-14 Phosphate derivatives of pharmaceutical products

Publications (1)

Publication Number Publication Date
BRPI0409761A true BRPI0409761A (pt) 2006-05-09

Family

ID=31500850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409761-0A BRPI0409761A (pt) 2003-04-15 2004-04-14 complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo

Country Status (10)

Country Link
US (1) US20070042999A1 (pt)
EP (1) EP1615650A4 (pt)
JP (1) JP2006523623A (pt)
KR (1) KR20060014370A (pt)
CN (1) CN1774254A (pt)
AU (2) AU2003901813A0 (pt)
BR (1) BRPI0409761A (pt)
CA (1) CA2521842A1 (pt)
MX (1) MXPA05010508A (pt)
WO (1) WO2004091636A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
BR0211673A (pt) * 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
ATE487456T1 (de) * 2001-12-13 2010-11-15 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
EP1589964B1 (en) * 2003-01-17 2011-11-23 Vital Health Sciences Pty Ltd. Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
JP4847437B2 (ja) * 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
WO2006092024A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
IL267006B2 (en) * 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN112824426B (zh) * 2019-11-21 2022-02-11 上海喀露蓝科技有限公司 一种别孕烯醇酮膦酰胺衍生物、其制备方法及其在医药上的用途
WO2022155656A1 (en) 2021-01-13 2022-07-21 Rodan & Fields, Llc Cosmetic compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195393A (ja) * 1986-02-21 1987-08-28 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造方法
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
WO2000069865A1 (en) * 1999-05-14 2000-11-23 Swig Pty Ltd Improved process for phosphorylation and compounds produced by this process
CA2747954C (en) * 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
AU2002214820B2 (en) * 2000-11-14 2003-08-14 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
BR0211673A (pt) * 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
ATE487456T1 (de) * 2001-12-13 2010-11-15 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier

Also Published As

Publication number Publication date
KR20060014370A (ko) 2006-02-15
AU2003301764B8 (en) 2006-03-30
US20070042999A1 (en) 2007-02-22
AU2003901813A0 (en) 2003-05-01
EP1615650A4 (en) 2006-06-14
WO2004091636A1 (en) 2004-10-28
CN1774254A (zh) 2006-05-17
AU2003301764B2 (en) 2006-03-23
MXPA05010508A (es) 2005-11-16
JP2006523623A (ja) 2006-10-19
EP1615650A1 (en) 2006-01-18
CA2521842A1 (en) 2004-10-28
AU2003301764A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
BRPI0409761A (pt) complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo
AR019690A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
AR003415A1 (es) Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
EE04018B1 (et) Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised
ATE223413T1 (de) Neuartige verbindungen
UY27552A1 (es) 17a- alquil- 17b- oxi-estratrienos y productos intermediarios para su preparacinn, uso de los 17a-alquil-17b-oxi-estratrienos para obtener medicamentos y preparados farmacéuticos.
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
AU2002316811A1 (en) Stable formulation of modified glp-1
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
ATE343374T1 (de) Fluticasonpropionat arzneizubereitung
ATE289801T1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
BR0115952A (pt) Composição de emulsão para administração terapêutica, método de administração, processo para o preparo de uma formulação contendo derivados de fosfato de agentes de transferência de elétrons
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
NZ502840A (en) High pressure homogenisation method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.